‘Dif­fi­cult to go pub­lic with’: Spar­ingVi­sion turns to ex­ist­ing back­ers to fund its first two oc­u­lar gene ther­a­py tri­als

On the hunt to im­prove up­on the foun­da­tions of Lux­tur­na by cre­at­ing a gene ther­a­py that it hopes can be giv­en to a broad­er swath of pa­tients with a rare reti­nal dis­ease than its Big Phar­ma ri­val, Spar­ingVi­sion has se­cured an­oth­er round of fi­nanc­ing. But it didn’t come easy.

The Paris and Philadel­phia biotech’s lead­er­ship be­gan the Se­ries B process in Jan­u­ary, and at that time, they agreed that if by the end of spring it proved to be “too chal­leng­ing, im­pos­si­ble or that the val­ue that we were look­ing for was just im­pos­si­ble to ob­tain, we were go­ing to fo­cus on an in­sid­er-on­ly round,” CEO and pres­i­dent Stéphane Bois­sel told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER